Search Results - "Abdeddaim, C."

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network by Derquin, F., Floquet, A., Hardy-Bessard, A.C., Edeline, J., Lotz, J.P., Alexandre, J., Pautier, P., Angeles, M.A., Delanoy, N., Lefeuvre-Plesse, C., Cancel, M., Treilleux, I., Augereau, P., Lavoue, V., Kalbacher, E., Berton Rigaud, D., Selle, F., Nadeau, C., Gantzer, J., Joly, F., Guillemet, C., Pomel, C., Favier, L., Abdeddaim, C., Venat-Bouvet, L., Provansal, M., Fabbro, M., Kaminsky, M.C., Lortholary, A., Lecuru, F., Coquard, I. Ray, de La Motte Rouge, T.

“…Malignant ovarian germ cell tumors are rare tumors, affecting young women with a generally favorable prognosis. The French reference network for Rare Malignant…”
Get full text

Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery by El Hajj, H., Vanseymortier, M., Hudry, D., Bogart, E., Abdeddaim, C., Leblanc, E., Le Deley, M.C., Narducci, F.

“…Ovarian cancer remains the most lethal gynecologic malignancy with high recurrence rates. Because recurrence involves primarily the peritoneum, intraperitoneal…”
Get full text

952P Neutrophil-to-lymphocyte ratio (NLR) and survival in recurrent or metastatic head and neck cancer patients treated with immunotherapy by Franco, A., Tresch, E., Sakji, I., Makhloufi, S., Abdeddaim, C., Julieron, M., Dansin, E., Chevalier, D., Mouawad, F., Lefebvre, G.

Get full text

733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study by Freyer, G., Floquet, A., Tredan, O., Langlois-Jacques, C., Selle, F., Abdeddaim, C., Leary, A., Dubot, C., Fabbro, M., Gladieff, L., Sajous, C.

Get full text

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial by Kurtz, Jean-Emmanuel, Pujade-Lauraine, Eric, Oaknin, Ana, Belin, Lisa, Leitner, Katharina, Cibula, David, Denys, Hannelore, Rosengarten, Ora, Rodrigues, Manuel, de Gregorio, Nikolaus, Martinez García, Jeronimo, Petru, Edgar, Kocián, Roman, Vergote, Ignace, Pautier, Patricia, Schmalfeldt, Barbara, Gaba, Lydia, Polterauer, Stephan, Mouret Reynier, Marie-Ange, Sehouli, Jalid, Churruca, Cristina, Selle, Frédéric, Joly, Florence, D'Hondt, Véronique, Bultot-Boissier, Émilie, Lebreton, Coriolan, Lotz, Jean-Pierre, Largillier, Rémy, Heudel, Pierre-Etienne, Heitz, Florian

“…Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI)…”
Get full text

SO-9 Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study by André, T., Berton, D., Curigliano, G., Arkenau, H., Trigo, J., Ellard, S., Moreno, V., Abdeddaim, C., Antón, A., Kumar, S., Guo, W., Im, E., Starling, N.

Get full text

758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial by Saint-Ghislain, M., Abdeddaim, C., Chaltiel, R., Cousin, S., Gomez-Roca, C.A., Borel, C., Ghiringhelli, F., Vansteene, D., Bigot, F., Jeannot, E., Guerini Rocco, E., Frige, G., Mazzarella, L., Francisco, M., Legrand, F., Jimenez, M., Halladjian, M., Kamal, M., Cabarrou, B., Le Tourneau, C.

Get full text

935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM) by Galot, R., Le Tourneau, C., Licitra, L.F.L., Even, C., Daste, A., Henry, S., Borel, C., Abdeddaim, C., Seront, E., Prevost, J.B., Rutten, A., Saada, E.B., Rolland, F., Livi, L., Specenier, P.M.C., Leys, J., Olungu, C., Fortpied Lefevre, C., Joaquim, A., Machiels, J-P.

Get full text

923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial by Le Tourneau, C., Ghiringhelli, F., Saada, E.B., Chaltiel, R., Vansteene, D., Durando, X., You, B., Borel, C., Bigot, F., Abdeddaim, C., Marret, G., Jeannot, E., Guerini Rocco, E., Frige, G., Servant, N., Dupain, C., Kamal, M., Legrand, F., Jimenez, M., Filleron, T.

Get full text

557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial by Coutzac, C., Bigot, F., Vansteene, D., Dos Santos, M., Ghiringhelli, F., You, B., Lambert, A., Gomez-Roca, C.A., Abdeddaim, C., Neuzillet, C., Jeannot, E., Guerini Rocco, E., Frige, G., Mazzarella, L., Dupain, C., Kamal, M., Legrand, F., Jimenez, M., Filleron, T., Le Tourneau, C.

Get full text

752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial by Le Saux, O., Borel, C., Ghiringhelli, F., Bigot, F., Vansteene, D., Chaltiel, R., Cousin, S., Durando, X., Coquan, E., Abdeddaim, C., Jeannot, E., Guerini Rocco, E., Frige, G., Francisco, M., Halladjian, M., Kamal, M., Legrand, F., Jimenez, M., Cabarrou, B., Le Tourneau, C.

Get full text

528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant? by Thibault, G., Kfoury, M., Lorusso, D., Floquet, A., Ventriglia, J., Salaun, H., Moubarak, M., Rivoirard, R., Polastro, L., Favier, L., You, B., Berton-Rigaud, D., De La Motte Rouge, T., Mansi, L., Abdeddaim, C., Prulhiere, K., Lancry Lecomte, L., Provansal Gross, M., Dalban, C., Ray-Coquard, I.L.

Get full text

EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial by Perrier, L., Zarca, K., Cadet, T., Morelle, M., Cropet, C., Burges, A., Cecere, S.C., Palacio, I., Polterauer, S., Yoshida, H., Vuylsteke, P., Colombo, N., Nøttrup, T.J., Abdeddaim, C., El-Balat, A., Cinieri, S., Herrero, A., Kaminski, M.C., Pujade-Lauraine, E., Durand-Zaleski, I., Ray-Coquard, I.

Get full text

808MO Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study by Joly Lobbedez, F., Fabbro, M., Berton, D., Lequesne, J., Anota, A., Puszkiel, A., Floquet, A., Cancel, M., Bourgeois, H., Bengrine Lefevre, L., You, B., Pommeret, F., Lortholary, A., Spaeth, D., Martin-Babau, J., Abdeddaim, C., Kaminsky-Forrett, M-C., Petran, D., Provansal Gross, M., Brachet, P-E.

Get full text

829P Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial by Tredan, O., Provansal Gross, M., Abdeddaim, C., Chabaud, S., Anota, A., Treilleux, I., Pissaloux, D., Savoye, A.M., Hardy Bessard, A-C., Kalbacher, E., Floquet, A., Venat-Bouvet, L., Lortholary, A., Pop, O., Frenel, J-S., Cancel, M., Largillier, R., Louvet, C., Brocard, F., Ray-Coquard, I.L.

Get full text